eHealth2019: Five presentations
eHealth2019: Five presentations We take part in eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health” in
22.3.2019
Welcome Tuomas Lundström
ESiOR Oy experience is increasing… We welcome the 12th member of our team. Tuomas Lundström has joined our team as consultant and data scientist. Tuomas
19.10.2018
SHEOG: cost-effectiveness group @LinkedIn
Social and Health Economics and Outcomes Group (SHEOG) @LinkedIn https://www.linkedin.com/groups/8678341 You are welcome to join SHEOG! SHEOG @LinkedIn aims to encourage discussion about economic evaluation
25.6.2018
Virtual hospital 2.0 and Isaacus: presentations March 15, 2018
Virtual Hospital 2.0 mid-assessment and Isaacus pre-production project results are presented as podiums in an international eHealth2018 congress ESiOR takes part in the international eHealth
29.1.2018
Welcome Saara Huoponen
ESiOR Oy gets stronger… We welcome the 10th member of our team! Namely, ISPOR-awarded Saara Huoponen has joined our team as health economic consultant and
11.1.2018
Cost-effectiveness and budget impact analysis including a risk-sharing scheme
Conditional reimbursement context: An economic evaluation including a risk-sharing scheme A hybrid-modeling study that evaluated the clinical outcomes, cost-effectiveness, and budget impact of biologic rheumatoid
4.12.2017
Akseli Kivioja and Satu Rauhala: stronger service portfolio at ESiOR
Well-known Market Access professionals, Satu Rauhala and Akseli Kivioja, joined ESiOR on August 7th, 2017. Their joint experience is unique: Finnish Pharmaceuticals Pricing Board, pharma industry,
10.8.2017
Paid and unpaid work lost, hidden costs
The hidden costs of impairments in working ability and functional capacity among Finnish patients with inflammatory bowel diseases and rheumatoid arthritis were assessed in a
12.7.2017
RRMS: Considerable differences in the cost effectiveness of treatments
Multiple sclerosis (MS) progression and the cost-effectiveness analysis of first line disease modifying MS treatments (DMT) in Finland ESiOR studied relapsing-remitting MS (RRMS) progression and
24.2.2017
Professor pharmacoeconomics
Janne Martikainen, PhD (health economics), Adjunct Professor (economic evaluation of pharmaceuticals) in Turku University and one of ESiOR’s health economists and partners is now also
3.1.2017
Development project
Development of business and services portfolio Project’s goals are to innovate and develop new business, support business growth and strengthen national and international competitiveness of
21.12.2016
Nordic RWD conference, meet us there
ESiOR Ltd takes part in Nordic conference on Real World Data – Collaboration between pharma industry and Academia on November 29-30, 2016, in Helsinki. We
21.11.2016
